788822-08-2

Upstream product

• 172833-14-6 ((S)-5-tert-Butoxycarbonylamino-7-diazo-6-oxo-heptyl)-carbamic acid benzyl ester 
• 2389-45-9 6-(((benzyloxy)carbonyl)amino)-2-((tert butoxycarbonyl)amino)-hexanoic acid 
• 693222-12-7 (5-tert-butoxycarbonylamino-7-chloro-6-oxo-heptyl)-carbamic acid benzyl ester 

Downstream Products

• 693222-16-1 [5-(5-benzyloxycarbonylamino-1-chloroacetyl-pentylcarbamoyl)-5-tert-butoxycarbonylamino-pentyl]-carbamic acid benzyl ester 
• 872043-90-8 {4-[5-(2-benzyloxycarbonylamino-ethyl)-3-methyl-6-oxo-1,6-dihydro-pyrazin-2-yl]-butyl}-carbamic acid benzyl ester 
• 872043-88-4 {4-[5-(3-benzyloxycarbonylamino-propyl)-3-methyl-6-oxo-1,6-dihydro-pyrazin-2-yl]-butyl}-carbamic acid benzyl ester 
• 872043-72-6 C₆₃H₈₀N₈O₁₁ 
• 872043-70-4 C₆₄H₈₂N₈O₁₁ 
• 872043-69-1 C₆₅H₈₄N₈O₁₁ 
• 234450-04-5 {4-[5-(4-benzyloxycarbonylamino-butyl)-3-methyl-6-oxo-1,6-dihydro-pyrazin-2-yl]-butyl}-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Potent Dmt-Tic pharmacophoric δ- and μ-opioid receptor antagonists

A series of dimeric Dmt-Tic (2′,6′-dimethyl-L-tyrosyl-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid) analogues (8-14, 18-22) were covalently linked through diaminoalkane and symmetric or asymmetric 3,6-diaminoalkyl-2(1H)-pyrazinone moieties. All the c